Home: PCU
2|2003: Mitchell Benson, MD: Select publications
Select publications
Maximum androgen blockade in advanced prostate cancer:
An overview of the randomised trials. Prostate Cancer Trialists'
Collaborative Group. Lancet 2000;355(9214):1491-8. Abstract
Boccardo F et al. Bicalutamide monotherapy versus flutamide
plus goserelin in prostate cancer patients: Results of an Italian
Prostate Cancer Project study. J Clin Oncol 1999;17(7):2027-38.
Abstract
Denis LJ et al. Maximal androgen blockade: Final analysis
of EORTC Phase III trial 30853. EORTC Genito-Urinary Tract Cancer
Cooperative Group and the EORTC Data Center. Eur Urol 1998;33(2):144-51.
Abstract
Eisenberger MA et al. Bilateral orchiectomy with or without
flutamide for metastatic prostate cancer. N Engl J Med
1998;339(15):1036-42. Abstract
Labrie F et al. Can combined androgen blockade provide
long-term control or possible cure of localized prostate cancer?
Urology 2002;60(1):115-9. Abstract
Leibowitz RL et al. Treatment of localized prostate cancer
with intermittent triple androgen blockade: Preliminary results
in 110 consecutive patients. Oncologist 2001;6(2):177-82.
Abstract
Samson DJ et al. Systematic review and meta-analysis of
monotherapy compared with combined androgen blockade for patients
with advanced prostate carcinoma. Cancer 2002;95(2):361-376.
Abstract
Sarosdy MF et al. Does prolonged combined androgen blockade
have survival benefits over short-term combined androgen blockade
therapy? Urology 2000;55(3):391-5; discussion 395-6. Abstract
Schellhammer PF et al. Clinical benefits of bicalutamide
compared with flutamide in combined androgen blockade for patients
with advanced prostatic carcinoma: Final report of a doubleblind,
randomized, multicenter trial. Casodex Combination Study
Group. Urology 1997;50(3):330- 6. Abstract
Schmitt B et al. Combined androgen blockade with nonsteroidal
antiandrogens for advanced prostate cancer: A systematic review.
Urology 2001;57(4):727-32. Abstract
Tyrrell CJ et al. Comparison of an LH-RH analogue (Goeserelin
acetate, 'Zoladex') with combined androgen blockade in advanced
prostate cancer: Final survival results of an international multicentre
randomized-trial. International Prostate Cancer Study Group.
Eur Urol 2000;37(2):205- 11. Abstract
|
